Using nanoparticles that mimic VEGF to treat Spinocerebellar Ataxia Type 1
VEGF-Mimetic Supramolecular Nanoparticles for Treating Spinocerebellar Ataxia Type 1
This study is exploring a new way to help people with Spinocerebellar Ataxia Type 1 (SCA1) by creating tiny particles that can deliver a brain health protein to improve their condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10847354 on NIH RePORTER |
What this research studies
This research focuses on Spinocerebellar Ataxia Type 1 (SCA1), a progressive neurodegenerative disease. The team has discovered that a protein called ATXN1 affects levels of VEGF, a crucial factor for brain health, which are found to be low in SCA1. They aim to create nanoparticles that mimic VEGF to improve its delivery to brain cells, potentially enhancing neurovascular health. This innovative approach seeks to develop a new therapy that could significantly impact the treatment of SCA1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Spinocerebellar Ataxia Type 1.
Not a fit: Patients with other forms of ataxia or neurodegenerative diseases unrelated to SCA1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that improves brain health and function in patients with Spinocerebellar Ataxia Type 1.
How similar studies have performed: While the approach of using VEGF-mimetic nanoparticles is innovative, previous studies have shown promise in using VEGF for neurodegenerative conditions, indicating potential for success.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Opal, Puneet — Northwestern University at Chicago
- Study coordinator: Opal, Puneet
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.